Pfizer is expanding its cost-cutting drive to about $6.7 billion in savings, as the company works to offset the steep decline of its pandemic-era revenue.

Reporting second-quarter results on August 4, 2026, Pfizer added $1 billion in new targeted savings through 2029 on top of a programme begun in 2023 that originally aimed at $3.5 billion. The plan now also targets $1.5 billion in manufacturing savings.

The company framed the cuts as “productivity enhancements from technology and simplification efforts across our commercial, R&D and enabling functions.”

The COVID cliff

Revenue from the Comirnaty vaccine has fallen from $38 billion in 2022 to about $4.4 billion in 2025.

A decline of that magnitude has few parallels. Losing roughly $34 billion in annual revenue over three years is comparable to an entire large pharmaceutical company disappearing from the accounts, and the structure built to support it — manufacturing capacity, distribution, commercial organisation — was sized for the peak.

The transition was also predictable in direction and not in pace. Pandemic demand was always going to fall as populations were vaccinated, and how far it would settle depended on whether COVID vaccination became an annual routine on the scale of influenza. It has settled lower than that.

What the cuts actually mean

The corporate language deserves translation. “Productivity enhancements from technology and simplification efforts” across commercial, R&D and enabling functions describes headcount reduction, site consolidation and programme termination.

The R&D component is the one with long-term consequences. Commercial and administrative cuts affect present operations; reducing research spending affects products that would have reached market in the next decade, and the effect is invisible until it is irreversible.

The separate $1.5 billion manufacturing target reflects the specific problem of capacity built for pandemic volumes — facilities and supply agreements that no longer match demand.

The other pressures

Adding to the strain, five of Pfizer’s 13 cancer drugs posted lower sales in the quarter than a year earlier, and the company booked impairment charges of $3.8 billion on an experimental Seagen drug and $525 million on the sickle cell drug Oxbryta.

The Seagen write-down is the more significant. Pfizer acquired Seagen for roughly $43 billion in 2023, substantially to build an antibody-drug conjugate franchise as COVID revenue receded. Impairing a programme from that acquisition indicates the assets acquired are performing below the assumptions that justified the price.

Oxbryta is a different story: the drug was withdrawn from markets over safety findings after being acquired, so the impairment reflects a product that no longer exists commercially.

The quarter itself

Even so, the results were steady: revenue rose about 1% to $15 billion, with non-COVID drug sales up 5%.

That 5% is the number that matters most for the underlying business, since it describes the company excluding the pandemic distortion. Growth there means the base is expanding even as the COVID contribution shrinks.

Pfizer raised its full-year 2026 revenue forecast to $60.5–$62.5 billion and guided per-share earnings of $2.80 to $3.00.

Why investors approved

Shares rose about 1% on the news.

A positive response to cost cuts reflects a specific judgement: that the company is right-sizing rather than starving itself, and that management is acting rather than waiting for growth to solve the problem.

Why the acquisition strategy is under scrutiny

The impairments give sharper edge to a question about how Pfizer deployed its pandemic windfall.

The company emerged from 2021 and 2022 with extraordinary cash generation and a clear structural problem: that revenue would not persist, and the underlying business faced patent expirations later in the decade. Acquisition was the obvious response, and Pfizer spent heavily — Seagen for roughly $43 billion being the largest, alongside several smaller purchases.

Buying at that moment carried a specific disadvantage. Pfizer was a conspicuously cash-rich buyer with a visible need, which is not a strong negotiating position, and biotech valuations were still elevated relative to where they subsequently fell.

Whether the strategy worked will not be settled by one impairment. Antibody-drug conjugates remain a genuinely promising modality, and acquisitions of that scale are judged over a decade. What the write-downs establish is that the early evidence is running behind the assumptions — which is why cost discipline is now carrying weight that acquired growth was supposed to carry.

The looming issue is patent expiration on major products in the second half of the decade, which will remove further revenue independent of anything COVID-related. Cost discipline preserves earnings through that period; it does not replace the products. Business news, not investment advice.